Clinical Trial Detail

NCT ID NCT03979066
Title Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gulam Manji
Indications

pancreatic ductal adenocarcinoma

Therapies

Atezolizumab

Atezolizumab + PEGPH20

Age Groups: adult senior

No variant requirements are available.